Ovarian Cancer: Primary Chemotherapy
Since primary (first-line) platinum-based chemotherapy is a potentially curative treatment in conjunction with a debulking surgery for newly diagnosed ovarian cancer, it is important to explore these options with all patients regardless of age. Careful consideration of the dosing and scheduling of chemotherapy is required in our older patients. Although few prospective trials dedicated to older patients with newly diagnosed ovarian cancer have been performed, there have been several papers outlining outcomes and options for older patients. In this chapter, we will review the current guidelines and evidence for various intravenous and intraperitoneal chemotherapy regimens.
KeywordsOvarian cancer Primary chemotherapy Neoadjuvant chemotherapy Elderly patients
- 11.Farfield KM, Murray K, Lucas FL, et al. Completion of adjuvant chemotherapy and use of health services for old women with epithelial ovarian cancer. J Clin Oncol. 2011;29:3926.Google Scholar
- 14.Tredan O, Geay JF, Touzet S, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Ann Oncol. 2007;18:256–62.PubMedCrossRefGoogle Scholar
- 21.Tew WP, Java J, Chi D, et al. Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182). J Clin Oncol. 2010;28:15s (suppl; abstr 5030).Google Scholar
- 23.Schwartz PE. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology (Williston Park). 2008;22:1118–25.Google Scholar
- 29.Glasgow MA, Yu H, Rutherford TJ, et al. Neoadjuvant chemotherapy is an effective way of managing women with advanced stage ovarian cancer (FIGO stage IIIC and IV). J Surg Oncol. 2012. doi: 10.1002/jso.23171.
- 31.Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10–4.PubMedCrossRefGoogle Scholar
- 34.Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.PubMedGoogle Scholar
- 37.Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–9.PubMedCrossRefGoogle Scholar